AKEBIA THERAPEUTICS, INC.

(AKBA)
  Report
Delayed Nasdaq  -  04:00 2022-08-12 pm EDT
0.4134 USD   +3.71%
08/11PUBLIC DISCLOSURE VS. CONFIDENTIALITY PROTECTION : The FCA Finds The Proper Balance
AQ
08/05Akebia Therapeutics Announces Initial Findings from Investigator-Sponsored Clinical Study Evaluating Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome
AQ
08/04AKEBIA THERAPEUTICS : Q2 Earnings Snapshot
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Akebia Therapeutics : Announces Presentations at ERA-EDTA Virtual Congress 2021

06/03/2021 | 08:02am EDT

CAMBRIDGE, Mass., June 3, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced presentations of data from the global Phase 3 program for vadadustat at the European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Virtual Congress 2021, to be held June 5 - June 8, 2021.

Abstracts are now available online within Nephrology Dialysis Transplantation (NDT), the official journal for the ERA-EDTA.

Akebia-sponsored mini-oral sessions are:  

For more information on ERA-EDTA Virtual Congress 2021, visit: https://www.era-edta.org/en/virtualcongress2021/.

About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. The Company was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

About Vadadustat
Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor designed to mimic the physiologic effect of altitude on oxygen availability. At higher altitudes, the body responds to lower oxygen availability with stabilization of hypoxia-inducible factor, which can lead to increased red blood cell production and improved oxygen delivery to tissues. Vadadustat recently completed its global Phase 3 development program for the treatment of anemia due to CKD. Vadadustat is not approved by the U.S. Food and Drug Administration (FDA) or any regulatory authority with the exception of Japan's Ministry of Health, Labour and Welfare (MHLW). In Japan, vadadustat is approved as a treatment for anemia due to CKD in both dialysis-dependent and non-dialysis dependent adult patients.

Investor Contact
Kristen K. Sheppard, Esq.
Ir@akebia.com

 

Cision
View original content to download multimedia:http://www.prnewswire.com/news-releases/akebia-therapeutics-announces-presentations-at-era-edta-virtual-congress-2021-301304979.html

SOURCE Akebia Therapeutics


© PRNewswire 2021
All news about AKEBIA THERAPEUTICS, INC.
08/11PUBLIC DISCLOSURE VS. CONFIDENTIALIT : The FCA Finds The Proper Balance
AQ
08/05Akebia Therapeutics Announces Initial Findings from Investigator-Sponsored Clinical Stu..
AQ
08/04AKEBIA THERAPEUTICS : Q2 Earnings Snapshot
AQ
08/04AKEBIA THERAPEUTICS : Reports Second Quarter 2022 Financial Results and Recent Business Hi..
PU
08/04AKEBIA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition ..
AQ
08/04TRANSCRIPT : Akebia Therapeutics, Inc., Q2 2022 Earnings Call, Aug 04, 2022
CI
08/04Akebia Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Month..
CI
08/04AKEBIA THERAPEUTICS, INC. : Results of Operations and Financial Condition, Regulation FD D..
AQ
08/04Akebia Therapeutics, Inc. Revises Earnings Guidance for the Full Year 2022
CI
08/04Earnings Flash (AKBA) AKEBIA THERAPEUTICS Posts Q2 Revenue $126.8M
MT
More news
Analyst Recommendations on AKEBIA THERAPEUTICS, INC.
More recommendations